AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15947613 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 210
Study 15947613 — intervention group
Group type: COMPARATOR
Intervention: Phloroglucinol
Number of subjects: 210
Study 15947613 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 210
Study 12837122 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of the wrist
Number of subjects: 28
Study 12837122 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound, friction massage, and muscle stretching and strengthening exercises
Number of subjects: 28
Study 11006069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interventions utilizing interactive telephone counseling
Number of subjects: 22
Study 11006069 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions such as patient reminders
Number of subjects: 22
Study 11006069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociologic intervention using video-taped peer discussions
Number of subjects: 22
Study 11006069 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple types of strategies
Number of subjects: 22
Study 9229322 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FU/FA
Number of subjects: 44
Study 9229322 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FU/FA/C
Number of subjects: 44
Study 9229322 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FU/FA/C/E
Number of subjects: 44
Study 1334445 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nedocromil sodium eye drops (twice daily)
Number of subjects: 185
Study 1334445 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eye drops (four times daily)
Number of subjects: 185
Study 1334445 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 185
Study 1334445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium eye drops
Number of subjects: 185
Study 1334445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate eye drops
Number of subjects: 185
Study 3881088 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid formulations
Number of subjects: 0
Study 3881088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoconstriction assay
Number of subjects: 0
Study 30517100 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sport participation at age 12
Number of subjects: 4033
Study 30517100 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity measures at age 12
Number of subjects: 4033
Study 25857847 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. parecoxib sodium 40 mg
Number of subjects: 64
Study 25857847 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo (saline) 2 mL
Number of subjects: 64
Study 24534413 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM with mother's recorded voice
Number of subjects: 94
Study 24534413 — intervention group
Group type: COMPARATOR
Intervention: No PAM (control)
Number of subjects: 94
Study 22398072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up
Number of subjects: 140
Study 22398072 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 140
Study 20592006 — intervention group
Group type: EXPERIMENTAL
Intervention: ATM therapy (N=47)
Number of subjects: 90
Study 20592006 — intervention group
Group type: COMPARATOR
Intervention: Control condition (financial workbook review, N=43)
Number of subjects: 90
Study 18534139 — intervention group
Group type: EXPERIMENTAL
Intervention: LTRA(+) (pranlukast, treated for 3 months)
Number of subjects: 29
Study 18534139 — intervention group
Group type: COMPARATOR
Intervention: LTRA(-) (no pranlukast)
Number of subjects: 29
Study 18534139 — intervention group
Group type: EXPERIMENTAL
Intervention: LTRA(+) (pranlukast)
Number of subjects: 29
Study 16001906 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training
Number of subjects: 30
Study 16001906 — intervention group
Group type: COMPARATOR
Intervention: Traditional training with biofeedback
Number of subjects: 30
Study 12461494 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 microg/day (group 1)
Number of subjects: 47
Study 12461494 — intervention group
Group type: EXPERIMENTAL
Intervention: 62.5 microg/day for 3 days, then 37.5 microg/day (group 2)
Number of subjects: 47
Study 12461494 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/day (group 3)
Number of subjects: 47
Study 10367992 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients listening to combat sounds
Number of subjects: 35
Study 10367992 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients listening to white noise
Number of subjects: 35
Study 10367992 — intervention group
Group type: COMPARATOR
Intervention: Control groups (combat-exposed subjects without PTSD and healthy control subjects) listening to combat sounds
Number of subjects: 35
Study 10367992 — intervention group
Group type: COMPARATOR
Intervention: Control groups (combat-exposed subjects without PTSD and healthy control subjects) listening to white noise
Number of subjects: 35
Study 7562765 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy + routine drug therapy
Number of subjects: 121
Study 7562765 — intervention group
Group type: COMPARATOR
Intervention: Routine drug therapy
Number of subjects: 121
Study 1696795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) as volume replacement
Number of subjects: 0
Study 1696795 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP) and human albumin (HA)
Number of subjects: 0
Study 7438972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenoterol 2.5 mg
Number of subjects: 12
Study 7438972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenoterol 5 mg
Number of subjects: 12
Study 7438972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenoterol 7.5 mg
Number of subjects: 12
Study 7438972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31772506 — intervention group
Group type: EXPERIMENTAL
Intervention: High day 1 dsDNA levels (>median; 366 ng/ml)
Number of subjects: 259
Study 27852999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin vaccine
Number of subjects: 60
Study 27852999 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin purified protein derivative
Number of subjects: 60
Study 27852999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study 26087078 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease agency language assigned to humans (e.g., 'I developed cancer')
Number of subjects: 499
Study 26087078 — intervention group
Group type: EXPERIMENTAL
Intervention: Death-approach language (e.g., 'as death closes in on patients')
Number of subjects: 499
Study 26087078 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-approach language (e.g., 'as patients close in on death')
Number of subjects: 499
Study 26087078 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation and identification
Number of subjects: 499
Study 23327232 — intervention group
Group type: COMPARATOR
Intervention: Saliva contamination after primer application (group 2)
Number of subjects: 180
Study 23327232 — intervention group
Group type: COMPARATOR
Intervention: Saliva contamination after primer and before bonding (group 3)
Number of subjects: 180
Study 23327232 — intervention group
Group type: COMPARATOR
Intervention: Saliva contamination after bonding (group 4)
Number of subjects: 180
Study 23327232 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva contamination after light polymerization of the bonding agent (group 5)
Number of subjects: 180
Study 23327232 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva contamination after light polymerization with removal of contaminated layer (group 6)
Number of subjects: 180
Study 23327232 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 180
Study 21358561 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clonazepam (1 mg once daily) and Deanxit for 3 weeks
Number of subjects: 0
Study 21358561 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam (1 mg once daily) and placebo for 3 weeks
Number of subjects: 0
Study 19952790 — intervention group
Group type: EXPERIMENTAL
Intervention: Job-specific occupational health education program
Number of subjects: 205
Study 19952790 — intervention group
Group type: COMPARATOR
Intervention: Conventional program
Number of subjects: 205
Study 17971582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 60
Study 17971582 — intervention group
Group type: COMPARATOR
Intervention: Two-Dimensional Radiation Therapy (2DRT)
Number of subjects: 60
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 0.5 mg after oral placebo (OP)
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 0.5 mg after 80 mg isosorbide dinitrate (ISDN)
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 0.5 mg after 120 mg isosorbide dinitrate (ISDN)
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) after long-term OP therapy
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) after long-term 80 mg ISDN therapy
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) after long-term 120 mg ISDN therapy
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg once-daily
Number of subjects: 38
Study 15115903 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg once-daily
Number of subjects: 38
Study 11763107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg t.i.d.)
Number of subjects: 16
Study 11763107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9893926 — intervention group
Group type: EXPERIMENTAL
Intervention: Timonil retard (test formulation)
Number of subjects: 21
Study 9893926 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 21
Study 9893926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 21
Study 8061389 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-fluorouracil, its analogues, and mitomycin C)
Number of subjects: 0
Study 8061389 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 0
Study 2657837 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 2657837 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone
Number of subjects: 0
Study 2657837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 947849 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine (700 IU)
Number of subjects: 399
Study 947849 — intervention group
Group type: COMPARATOR
Intervention: Whole virus vaccine (2100 IU)
Number of subjects: 399
Study 947849 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine (2100 IU)
Number of subjects: 399
Study 947849 — intervention group
Group type: COMPARATOR
Intervention: Split vaccine (800 IU)
Number of subjects: 399
Study 31415827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 170
Study 29064884 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics and intravenous antimicrobial prophylaxis
Number of subjects: 335
Study 29064884 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antimicrobial prophylaxis alone
Number of subjects: 335
Study 29546345 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin use before diagnosis
Number of subjects: 1225
Study 29546345 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin use during treatment
Number of subjects: 1225
Study 29546345 — intervention group
Group type: EXPERIMENTAL
Intervention: Other supplement use (before diagnosis or during treatment)
Number of subjects: 1225
Study 25023433 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous hyoscine-N-butyl bromide (HBB)
Number of subjects: 2
Study 25023433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL saline)
Number of subjects: 2
Study 24175604 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% burst duty cycle of medium-frequency alternating current
Number of subjects: 0
Study 24175604 — intervention group
Group type: COMPARATOR
Intervention: 35% burst duty cycle of medium-frequency alternating current
Number of subjects: 0
Study 24175604 — intervention group
Group type: COMPARATOR
Intervention: 50% burst duty cycle of medium-frequency alternating current
Number of subjects: 0
Study 24175604 — intervention group
Group type: COMPARATOR
Intervention: All burst duty cycles (20%, 35%, 50%)
Number of subjects: 0
Study 21786187 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet number
Number of subjects: 118
Study 21786187 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet secretion of ATP
Number of subjects: 118
Study 21786187 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of P-selectin
Number of subjects: 118
Study 21786187 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte- and endothelium-derived microvesicles
Number of subjects: 118
Study 21786187 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived and total procoagulant phosphatidylserine-positive microvesicles
Number of subjects: 118
Study 18206146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionomycin for artificial oocyte activation (10 muM for 10 minutes)
Number of subjects: 87
Study 18206146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no artificial oocyte activation)
Number of subjects: 87
Study 17163361 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 73
Study 17163361 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 73
Study 17163361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 12943178 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture treatment
Number of subjects: 100
Study 12943178 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 100
Study 11068398 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9586474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mk II self‐tapping implants
Number of subjects: 103
Study 9586474 — intervention group
Group type: COMPARATOR
Intervention: Standard implants
Number of subjects: 103
Study 9586474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implants
Number of subjects: 103
Study 9586474 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary implants
Number of subjects: 103
Study 8466895 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol
Number of subjects: 16
Study 8466895 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic alpha-tocopherol
Number of subjects: 16
Study 8466895 — intervention group
Group type: COMPARATOR
Intervention: Both vitamin E groups
Number of subjects: 16
Study 3544084 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (mustine, Oncovin, procarbazine, prednisone)
Number of subjects: 299
Study 3544084 — intervention group
Group type: COMPARATOR
Intervention: LOPP (Leukeran substituted for mustine)
Number of subjects: 299
Study 31385800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight iron dextran (1 g)
Number of subjects: 60
Study 31385800 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 60
Study 31385800 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 60
Study 29332050 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental L (10 mg), MZ (10 mg), and Z (2 mg) daily for 12 months
Number of subjects: 91
Study 29332050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 26610430 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (1000 mg T undecanoate)
Number of subjects: 67
Study 26610430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 25445074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for late-life GAD, 10 sessions
Number of subjects: 150
Study 22245877 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinic agent (solifenacin)
Number of subjects: 33
Study 22245877 — intervention group
Group type: COMPARATOR
Intervention: No antimuscarinic agent
Number of subjects: 33
Study 21158371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection
Number of subjects: 4
Study 17323071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal followed 2 h later by a bout of 1 h moderate (60% max HR) exercise
Number of subjects: 10
Study 17323071 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal alone
Number of subjects: 10
Study 15930936 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized total knee arthroplasties
Number of subjects: 18
Study 15930936 — intervention group
Group type: COMPARATOR
Intervention: Posterior cruciate-retaining total knee arthroplasties
Number of subjects: 18
Study 12908378 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1000000
Study 12908378 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1000000
Study 12908378 — intervention group
Group type: COMPARATOR
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 1000000
Study 12908378 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1000000
Study 10561188 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically implanted venous access port (Port‐a‐Cath; Pharmacia, Canada Inc, Montreal, Québec, Canada)
Number of subjects: 119
Study 10561188 — intervention group
Group type: COMPARATOR
Intervention: Standard peripheral venous access
Number of subjects: 119
Study 8721162 — intervention group
Group type: COMPARATOR
Intervention: Control experiment - reproduction by pointing
Number of subjects: 0
Study 8721162 — intervention group
Group type: COMPARATOR
Intervention: Control experiment - visual reproduction
Number of subjects: 0
Study 8721162 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling-distance experiment - reproduction by pointing
Number of subjects: 0
Study 8721162 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling-distance experiment - visual reproduction
Number of subjects: 0
Study 1712835 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate disodium (EHDP) 5 mg/kg/d
Number of subjects: 173
Study 1712835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 7040950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose‐electrolyte solution containing 90 mmol of sodium per liter
Number of subjects: 146
Study 7040950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose‐electrolyte solution containing 50 mmol of sodium per liter
Number of subjects: 146
Study 7040950 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous therapy
Number of subjects: 146
Study 31658335 — intervention group
Group type: EXPERIMENTAL
Intervention: RA + FM
Number of subjects: 42
Study 31658335 — intervention group
Group type: EXPERIMENTAL
Intervention: RME + FM (pubertal group)
Number of subjects: 42
Study 31658335 — intervention group
Group type: EXPERIMENTAL
Intervention: RME + FM (postpubertal group)
Number of subjects: 42
Study 31658335 — intervention group
Group type: EXPERIMENTAL
Intervention: SARME + FM
Number of subjects: 42
Study 29529222 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 3293
Study 29529222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3293
Study 27039178 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT2BFiT mHealth program (3-month intervention with 6-month maintenance)
Number of subjects: 250
Study 27039178 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT2BFiT mHealth program
Number of subjects: 250
Study 23985706 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 148
Study 23985706 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir (TDF)
Number of subjects: 148
Study 23985706 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 148
Study 22348071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with EMLA cream
Number of subjects: 50
Study 22348071 — intervention group
Group type: COMPARATOR
Intervention: Dry wicks
Number of subjects: 50
Study 22348071 — intervention group
Group type: COMPARATOR
Intervention: Wet wicks
Number of subjects: 50
Study 22348071 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 50
Study 20545664 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous bubble trap in MECC system
Number of subjects: 40
Study 20545664 — intervention group
Group type: COMPARATOR
Intervention: Standard minimized extracorporeal circuit without venous bubble trap
Number of subjects: 40
Study 17426329 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Number of subjects: 70
Study 17426329 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 15781142 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available sports drink (Test)
Number of subjects: 10
Study 15781142 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (Control)
Number of subjects: 10
Study 12225711 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 3156
Study 10217908 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Number of subjects: 21
Study 7818159 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-wave Doppler ultrasound
Number of subjects: 116
Study 7818159 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-wave Doppler examination
Number of subjects: 116